Navigation Links
Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:4/26/2013

CAMBRIDGE, Mass., April 26, 2013 /PRNewswire/ -- Epizyme, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock.  The number of shares to be offered and the price range for the offering have not been determined.

Citigroup, Cowen and Company, LLC and Leerink Swann LLC will act as joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. will act as co-managers for the offering.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (tel: 800-831-9146); Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by calling (631) 274-2806, or by faxing (631) 254-7140; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Mass., 02110, or by email at Syndicate@Leerink.com or by phone at 1-800-808-7525.

About Epizyme, Inc.
Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing).

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Contact:

Jason P. Rhodes
Chief Financial Officer
Epizyme, Inc.
Ph: 617-803-3888
Email: jrhodes@epizyme.com

Megan Lustig
Spectrum
Ph: 202.955.6222 ext. 2586
Email: mlustig@spectrumscience.com

 


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
2. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
3. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
4. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
5. Sunpeaks Ventures Files Defamation Lawsuit
6. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
7. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
8. DataMotion Files Provisional Patent for Technology that Enables Easy and Secure Doctor-Patient Email Interaction
9. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
10. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
11. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017  Today, Analytics 4 Life ... devices, announced its expansion into JLABS @ ... life science incubators. As a resident in the space, ... medical device development and commercialization expertise. JLABS ... science innovation center that provides a flexible environment for ...
(Date:1/15/2017)... , January 16, 2017 Der ... Kollagenprodukten für die Regeneration des menschlichen Gewebes, gibt die ... mit sofortiger Wirkung bekannt. ... Bill Allan ... Er bekleidete eine Reihe von Geschäftsführer- und anderen Führungspositionen ...
(Date:1/13/2017)... 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), ... Finance and Investment Banking at Eli Lilly & Company, has ... Bott brings over 28 years of senior financial and executive ... ... has established a significant leadership position in financial and business ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine recently queried ... counties for 2017. Almost 1,000 nominations were submitted and a little over 500 ... were announced the magazine’s January 2017 issue . , Under the category ...
(Date:1/15/2017)... NJ (PRWEB) , ... January 15, 2017 , ... ... firm located in Montclair, NJ is pleased to announce that it will be ... is located in Montclair and Glen Ridge townships, servicing all surrounding towns. The ...
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... AgileMinder develops ... , The Emoji Scale is now available on Apple as a fun, free ... ratings simply by choosing one of the ten color coded values on The Emoji ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... The 18th ... Avenida America hotel on March 3-4, 2017. This Congress is expertly designed to ... the management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, ...
(Date:1/13/2017)... ... January 13, 2017 , ... With the increasing public ... of providing additional organic alternatives for customers who have grown more conscious about ... line of all-natural activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg ...
Breaking Medicine News(10 mins):